PPParvin Pourmasoumi

Parvin Pourmasoumi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Parvin Pourmasoumi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Abdollah Amini

    Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Farshid Zamani

    Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mohammad Bayat

    Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abdollah Amini

    Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Aghdass Rasouli-Nia

    Department of Oncology, Faculty of Medicine, University of Alberta, Edmonton, AB T6G 1Z2, Canada

    1 shared publication
  • Ali Moradi

    Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma

    by Parvin Pourmasoumi, Farshid Zamani, Mohammad Bayat, Abdollah Amini

    Introduction: Glioblastoma (GBM) has a poor prognosis, and temozolomide (TMZ) therapy is limited by a short half-life and insufficient intratumoral availability. We developed a bevacizumab (BVZ)-functionalized, exosome-associated chitosan nanocomposite loaded with TMZ (BVZ–Exo@CS–TMZ) as a multifunctional biohybrid platform for experimental glioma therapy. Methods: CS–TMZ nanoparticles were prepared by ionotropic gelation, non-covalently associated with adipose-derived stromal cell exosomes (Exo), and functionalized with BVZ via EDC/NHS conjugation to accessible surface carboxyl groups. The Exo preparation was characterized by Western blotting, while the final formulation was characterized by FTIR, XRD, FESEM, TEM, DLS, zeta potential, and VEGF-binding ELISA. Apparent TMZ retention, loading, and release were quantified by UV–visible spectrophotometry. Biological activity was evaluated in C6 glioma cells and in a proof-of-concept intracerebral C6 glioma-bearing rat model. Results: BVZ–Exo@CS–TMZ showed quasi-spherical morphology, a hydrodynamic diameter of 195.6 ± 6.7 nm, a PDI of 0.21 ± 0.03, and a zeta potential of − 50.12 mV. Western blotting detected the EV-associated markers CD9, CD63, and CD81 in the Exo preparation, whereas calnexin was not detected. ELISA showed 74.9 ± 2.9% retained VEGF-binding activity after conjugation and washing. Apparent TMZ entrapment efficiency was 68.50 ± 2.15%, with a final trehalose-free loading of 15.96 ± 0.18 wt%. Apparent release over 96 h was acid-accelerated (Korsmeyer–Peppas n = 0.448– 0.497). In C6 cells, the formulation reduced metabolic viability to 37.9% and lowered the TMZ-equivalent apparent IC50 from 99.4 to 55.6 μM. In vivo, it produced the smallest tumour area and fewest H&E-defined vascular-like regions, with increased Tp53, Bax, and Casp3 transcripts and reduced pri-/pre-miR-21 precursor RNA. Conclusion: These findings support BVZ–Exo@CS–TMZ as a proof-of-concept EV-associated chitosan nanomedicine strategy for experimental glioma. Further pharmacokinetic, biodistribution, safety, and mechanistic validation in more clinically relevant glioblastoma models is required.

  • Open Access

    CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation

    by Parvin Pourmasoumi, Ali Pourmasoumi, Farshid Zamani, Abdollah Amini, Shiva Shokri

    Chimeric antigen receptor (CAR) T-cell therapy has delivered unprecedented clinical benefit in hematological malignancies, yet its successful translation to solid tumors remains a major unmet clinical challenge. Glioblastoma (GBM), the most aggressive primary brain tumor, exemplifies the barriers confronting cellular immunotherapy, including profound intratumoral heterogeneity, antigenic escape, a highly immunosuppressive tumor microenvironment, and anatomical constraints imposed by the blood–brain barrier. Together, these features limit CAR-T cell trafficking, persistence and sustained antitumor activity in the central nervous system.In this Review, we examine recent advances in next-generation CAR-T engineering strategies aimed at overcoming these obstacles in GBM. Key developments include multi-antigen and logic-gated CAR designs to mitigate tumor immune evasion, armored CAR-T cells capable of cytokine delivery or resistance to suppressive mediators such as TGF-β, and checkpoint-resistant constructs to counteract functional exhaustion. We also highlight emerging delivery paradigms — including locoregional administration, viral vectors and nanotechnology-enabled platforms — designed to enhance blood–brain barrier penetration and intratumoral retention. Furthermore, we discuss combinatorial strategies integrating CAR-T therapy with immune checkpoint blockade, oncolytic virotherapy and other immunomodulatory interventions to remodel the hostile glioblastoma microenvironment and amplify therapeutic efficacy. Finally, we address the principal translational challenges that must be resolved for broader clinical implementation, including neurotoxicity, manufacturing scalability and the development of predictive preclinical models.Collectively, these multidisciplinary advances provide a roadmap for optimizing CAR-T cell therapy in glioblastoma and accelerating its translation toward durable clinical benefit.


  • In vitro photobiomodulation enhances human adipose-derived stem cell viability and exosome quality: a novel approach for regenerative medicine

    by Parvin Mirzaei Seresht, Abdollah Amini, Parvin Pourmasoumi, Masoumeh Hajihosseintehrani, Houssein Ahmadi, Bahareh Fallah, Fatemeh Zare, Soroush Bayat, Sufan Chien, Richard Albright, et al.

    Photobiomodulation (PBM), which stimulates cellular functions through light emission, has recently attracted significant attention in regenerative medicine. This study explores the effects of PBM with two wavelengths on human adipose-derived stem cells (ADSCs) and the characteristics of their secreted exosomes in vitro. ADSCs were isolated from human adipose tissue and treated with PBM with 650 nm and 810 nm wavelengths. The therapeutic effects, including cell viability, proliferation, and exosome characteristics, were evaluated using MTT assays, scanning electron microscopy (SEM), BCA assays to determine exosomal protein concentration, and Dynamic Light Scattering (DLS) to assess exosome size distribution. The results indicated that PBM at both wavelengths significantly enhanced ADSCs viability and proliferation, as confirmed by the MTT assay (p = 0.008 for 650 nm laser and p = 0.007 for 810 nm laser). Additionally, exosome analysis revealed that exosomes from PBM-treated groups exhibited a higher protein concentration and an average size of around 86 nm, as measured by BCA and DLS. We concluded that PBM with 650 nm and 810 nm wavelengths individually significantly enhances the proliferation and survival of ADSCs and improves exosome quality in vitro. The treatment increased exosomal protein concentration and improved size distribution, reflecting enhanced cell function. These findings suggest that PBM could be a promising stimulatory approach for improving ADSC-based therapies in regenerative medicine, particularly for tissue repair and chronic wound healing. Further research is needed to explore the molecular mechanisms and clinical applications of ADSCs under the influence of PBM.


  • Open Access

    Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors

    by Parvin Pourmasoumi, Seyed Abdolvahab Banihashemian, Farshid Zamani, Aghdass Rasouli-Nia, Davood Mehrabani, Feridoun Karimi-Busheri

    Glioblastomas are highly invasive brain tumors among perilous diseases. They are characterized by their fast proliferation and delayed detection that render them a significant focal point for medical research endeavors within the realm of cancer. Among glioblastomas, Glioblastoma multiforme (GBM) is the most aggressive and prevalent malignant brain tumor. For this, nanomaterials such as metallic and lipid nanoparticles and quantum dots have been acknowledged as efficient carriers. These nano-materials traverse the blood–brain barrier (BBB) and integrate and reach the necessary regions for neuro-oncology imaging and treatment purposes. This paper provides a thorough analysis on nanoparticles used in the diagnosis and treatment of brain tumors, especially for GBM.


  • Co-delivery of temozolomide and quercetin with folic acid-conjugated exosomes in glioblastoma treatment

    by Parvin Pourmasoumi, Majid Abdouss, Mona Farhadi, Seyed Behnamedin Jameie, Hossein Ali Khonakdar

    Aim: The study aims to improve glioblastoma multiforme (GBM) treatment by combining temozolomide (TMZ) and quercetin (Qct), using folic acid (FA)-conjugated exosomes to overcome TMZ resistance and enhance blood-brain barrier (BBB) penetration.Methods: Exosomes were isolated and after characterizing and modifying their surfaces with FA, drug loading of TMZ and Qct into exosomes was done. In vitro assays, including cell viability tests, RT-PCR, Western-blotting and flow-cytometry, were performed using U87MG and U251MG GBM cell lines. In vivo analysis included administering exosome-drug formulations to glioblastoma-bearing Wistar rats, monitored through optical imaging and PET scans, followed by post-mortem immunohistochemistry and histological examination.Results: The results showed successful exosome isolation and FA conjugation, with drug release studies indicating accelerated release of TMZ and Qct in acidic conditions, enhancing cytotoxicity. Immunofluorescence indicated greater exosome uptake in GBM cells due to FA conjugation. Cell viability assays demonstrated increased toxicity of the combination therapy, correlating with elevated apoptosis. In vivo studies revealed significant tumor size reduction, alongside increased apoptosis and reduced angiogenesis, particularly in the TMZ-Qct-Exo-FA group.Conclusion: FA-conjugated exosomes loaded with TMZ and Qct represent a promising strategy to enhance GBM treatment efficacy by improving drug delivery, apoptosis induction and inhibiting the PI3K/Akt/mTOR pathway.


  • BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review

    by Parvin Pourmasoumi, Ali Moradi, Mohammad Bayat

    Breast and ovarian cancers are significant global health concerns, and understanding their genetic underpinnings is essential for effective prevention and cure. This narrative review provides a comprehensive analysis of studies conducted between 1994 and June 2024, focusing on the link between specific mutations in the breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) and the associated risks of both breast and ovarian cancers. It encompasses the findings of various works, including observational studies and molecular profiling analyses. Conducted on large international cohorts, these studies present compelling evidence of the relationship between different BRCA1 and BRCA2 mutations and the varying risks of breast and ovarian cancer. Furthermore, this review highlights the significance of nonsense-mediated decay mutations and their impact on cancer risk, particularly concerning the age of breast cancer onset. The implications of these findings are far-reaching, offering valuable information for risk assessment and decision-making in managing individuals who carry BRCA1 or BRCA2 mutations. The molecular subtyping profile BluePrint is discussed as a potential tool for enhancing clinical care by aiding the selection of appropriate treatment options, such as endocrine therapy or chemotherapy, based on the tumor’s molecular characteristics. In conclusion, we establish a robust link between specific BRCA1 and BRCA2 gene mutations and increased susceptibility to breast and ovarian cancers. These mutations impact cancer onset age and severity, underscoring the need for targeted testing and screening. The current study enhances cancer detection, prevention, and cure strategies.